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Tulathromycin is a relatively new semi-synthetic macrolide antibiotic, a member 
of the triamilide group, approved primarly for the treatment of respiratory diseases in 
cattle and swine. Various genotoxicological studies indicated that tulathromycin is not 
genotoxic, but no available published data originate from the single-cell gel 
electrophoresis (Comet) assay. Therefore, the objective of this study was to examine 
whether it can induce primary DNA damage using in vitro Comet assay in isolated rat 
lymphocytes. Lymphocytes were treated with a broad spectrum of tulathromycin 
concentrations (from 1 to 100 µM) and co-treatment with an antioxidant, catalase (100 
IU/mL and 500 IU/mL) was performed.  The highest concentrations of tulathromycin (50 
and 100 µM) caused significant increase of DNA damage in rat lymphocytes and catalase 
did not significantly reduce the DNA-damaging effect of tulathromycin. The results of 
this study indicate that tulathromycin induces genotoxic effects at high concentrations, 
that catalase does not exert protective effect in this case. 
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INTRODUCTION 
          Tulathromycin is a triamilide macrolide antibiotic specifically developed for the 
treatment of bacterial respiratory diseases in cattle and swine (BENCHAOUI et al., 2004; EMEA, 
2004; EVANS, 2005). It was also confirmed as highly promising in the treatment of pulmonary 
abscesses in foals (VENNER et al., 2007) and respiratory infections in goats (WASHBURN et al., 
2007; CLOTHIER et al., 2011) and rabbits (АBO-EL-SOOUD et al., 2012). 
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Tulatromycin in vivo exists in a 9:1 ratio of 15-membered and 13-membered ring structures 
containing two attached sugar moieties (GALER et al., 2004; NOWAKOWSKI et al., 2004; EVANS, 
2005). The unique structural properties of tulathromycin enables its rapid dissemination from the 
plasma and extended residence time in tissues, primarily the lung, for up to 9 days (ABU-GHARBIEH 
et al., 2004; GALER et al., 2004; NOWAKOWSKI et al., 2004; EVANS, 2005; YAZAR, 2009). Not 
unlike other macrolides, it acts by binding to the 50 S subunit of bacterial ribosomes and blocking 
peptidyl transferase, which results in the dissociation of transfer RNA (tRNA), cessation of peptide 
translocation, and blocked protein synthesis (BENCHAOUI et al., 2004; EVANS, 2005).This drug is 
classified as bacteriostatic, but can also exhibit bactericidal activity at higher concentrations 
(BENCHAOUI et al., 2004; EMEA, 2004; EVANS, 2005). 
Tulathromycin may also cause oxidative stress and coagulation disorders (ER et al., 2011). 
In contrast to other macrolides, which are believed to have antioxidant effects in humans, 
tulathromycin may cause oxidative damage, possibly due to a different molecular structure and/or 
doses applied (ER et al., 2011). 
The genotoxic potential of tulathromycin was estimated in vivo (e.g. the rat micronucleus 
assay) and in vitro (the microbial gene mutation assay, mammalian cell (CHO/HGPRT) gene 
mutation assays, the human lymphocyte chromosome aberration test). The results indicated that 
tulathromycin is not genotoxic (EMEA, 2004). However, using flow cytometry WASHBURN et al. 
(2007) showed its genotoxic potential.  
Since there is only limited information on the genotoxicity of tulathromycin and that it was 
not evaluated using single cell gel electrophoresis (Comet) assay, this very sensitive method was 
applied to assess the DNA damaging effects in rat lymphocytes exposed to tulathromycin in order 
to provide additional genotoxicological data for this compound.  
 
MATERIALS AND METHODS 
Blood samples and treatment 
        The study was approved by the local Medical Ethics Committee at the Faculty of 
Veterinary Medicine, University of Belgrade. Heparinised blood samples (4 mL) were obtained 
from Wistar rats by venepuncture. The average body weight of rats was approximately 200 g. Four 
animals were used for each experimental point. Heparinised blood samples (sodium heparin, 
Galenika, Belgrade, Serbia) were immediately processed for isolation of lymphocytes on ficol 
gradient, as previously described (RADAKOVIC et al., 2014). The 50 µL of lymphocyte suspension 
was incubated in PBS solution containing tulathromycin, (CAS No 217500-96-4, Draxxin®, Pfizer 
Animal Healh, USA) at various concentrations, from 1 to 100 µM. The negative control was PBS 
and the positive 100 µM aqueous solution of H2O2. The treated lymphocytes were incubated at 
37°C for 1 h. The study was approved by the local Medical Ethics Committee and performed in 
accordance with The European Convention for the Protection of Vertebrate Animals used for 
Experimental and Scientific Purposes. 
 
The Comet assay 
Before the start of the experiment the cells were checked for viability using Trypan blue dye 
according to the method of  PHILLIPS (1973). The Comet assay was performed in three independent 
experiments on isolated rat peripheral blood lymphocytes. Microscope slides were precoated with 
1% double-distilled-water solution of normal agarose (Sigma, St. Louis, MO) and left at room 
temperature to dry. Lymphocytes were isolated using Amersham ficol gradient as described by 
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SOLTANI et al. (2008). The cell suspension in PBS was treated with tulathromycin at concentrations 
1 µM, 2 µM, 5 µM, 10 µM, 20 µM, 50 µM and 100 µM for 1 h at 37°C. After the treatment the 
cytotoxicity was determined by Trypan blue exclusion test and the cell suspensions were 
centrifuged at 2000 rpm for 5 min, the cell pellet mixed with an equal amount of 1% low-melting-
point agarose (Sigma) and rapidly placed on the precoated microscope slides, covered with cover-
slips and allowed to solidify for 5 min at 4°C. After removing the coverslips 1% agarose layer was 
added, the coverslips replaced, and left for 5 min at 4°C. Following the final removal of coverslips 
the slides were placed overnight in a lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% 
Triton X100 and 10% DMSO, pH 10 adjusted with NaOH). On completion of the lysis, the slides 
were placed in a buffer (10 M NaOH, 200 mM EDTA, pH 13) for 30 min at 4°C in the dark to 
allow DNA unwinding. Electrophoresis was carried out for 30 min. at 25 V and 300 mA. 
Afterwards, the slides were gently rinsed with a neutralising solution (0.4 M Tris base, pH 7.5) 
three times. The DNA was stained with 50 µL of ethidium bromide (20 µg/mL) per slide. The 
coded slides were examined and scored blind under a microscope equipped with a device for 
fluorescence recording at 400× magnification (Zeiss AXIO Imager M1 - Carl Zeiss Hamburg, 
Germany). DNA damage scoring was performed as described by COLLINS (2002). The cells (50 
cells/slide from duplicate slides per sample) were graded visually into five classes according to the 
tail size: no migration (A), low migration (B), medium migration (C), high migration (D) and 
extensive migration (E). The total comet scores (TCS), the migration of DNA, were calculated as 
TCS = 0 × A + 1 × B + 2 × C + 3 × D + 4 × E. 
 
Statistical analysis        
 The hypothesis of equality of the effects of different treatments was tested by the 
comparison of the average TCS. Depending on the values of coefficients of variation, an 
appropriate method was chosen to test the difference between the average TCSs: for homogenous 
datasets (cv<30%) the group test was a parametric test, ANOVA, and for heterogeneous datasets 
(cv >30%) a nonparametric, Kruskal Wallis test. Testing the differences between pairs of average 
TCSs the case of homogenous data in samples (cv <30%) was done with Tukey test, and in 
heterogeneous (cv >30%) with Mann-Whitney U test.  Due to large differences in the values for the 
positive control and other treatments logarithmic scale was used in Figures 1 and 2. 
Statistical analysis of the results obtained in the experiment was carried out using statistical 
software STATISTICA v.6. 
 
RESULTS  
Treatment with tulathromycin 
In this study the effects of tulathromycin in a wide range of concentrations, from 1 µM to 
100 µM, were evaluated. The viability of cells treated with adrenaline was greater than 90% in 
trypan blue exclusion test at the time of the assay.  The value of TCS ranged from 1 in the negative 
control and cells treated with 1 µM and 10µM of tulathromycin to 332 in the positive control 
(Table 1). The treatment of lymphocytes with 100 µM aqueous solution of H2O2 (positive control) 
resulted in homogenous TCS values (cv=11.13%), unlike all other treatments, which produced 
heterogeneous datasets (coefficient of variation ranged from 33.64 % at 100 µM of tulathromycin 
to 92.88 % at 20 µM of tulathromycin). Considering this, medians were used to quantify average 
values: the average value of TCSs varied from 5.5 in the presence of 2 µM of tulathromycin to 
279.5 in the positive control. 
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Table 1. Basic statistical parameters of TCSs in the experiment with various  concentrations of 
tulathromycin (n=4) 
Treatment 
 Median      Min. Max. Lower       
quartil 
Upper 
quartil 
Coef. of   
var. 
    Negative control (K-)  6.00 1.00 6.00 1.00 6.00 66.62 
        
 
 
   Thulathromicine 
2 µM 
5 µM 
10 µM                         
20 µM                         
50 µM 
100µM 
5.50 2.00 9.00 2.50 8.50 63.85 
8.50 2.00 11.00 4.00 11.00 58.12 
7.50 1.00 12.00 2.50 11.50 76.49 
7.00 2.00 18.00 2.00 15.00 92.88 
16.00 7.00 19.00 11.00 18.00 36.28 
18.50 11.00 24.00 13.00 23.00 33.64 
    Positive control (K+)   279.50 257.00 332.00 266.50 307.50 11.13 
     Negative control: 0 µM of tulathormycin (K-); positive control: 100 µM H2O2 (K+) 
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Figure 1. Effects of various tulathromycin concentrations on purified rat lymphocytes as the results of 
Kruskal-Wallis ANOVA and Mann-Whitney U test 
 Negative control: 0 µM of tulathormycin (K-); positive control: 100 µM H2O2 (K+). The same letters 
indicate the lack of significant difference (p>0.05), while an absence of the same letters denotes the 
presence of statistical significance between experimental points -  based on the results of Mann-
Whitney U test. 
 
As the data obtained in this experiment were heterogenous, nonparametric tests were 
applied. The Kruskal-Wallis test (H=20.73, p=0.008) showed that treatments exerted very 
significant different effects on TCSs. The Mann-Whitney U-test clearly showed that tulathromycin 
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in concentrations from 1 µM to 20 µM did not affect significantly the number of strand breaks in 
rat DNA in comparison with the negative control (Fig. 1). Only the two highest concentrations of 
tulathromycin (50 and 100 µM) caused significant increase of DNA damage in comparison to the 
negative control.   
Significantly higher TCS in the positive control in comparison to all other cultures 
confirmed that the test functioned properly.    
 
Co-treatment with catalase 
           In order to understand the mechanism of genotoxic effect of tulathromycin, the antioxidant 
catalase (CAS No 900-1-05-2; Sigma, St. Louis, USA) was used. The concentration of 
tulathromycin (100 µM) that produced the most severe DNA damage was chosen for co-treatment 
with the catalase (100 and 500 UI).  
           In this experiment, co-treatment with catalase, the average value of TCS ranged from 4.0 at 
500 IU of catalase to 307.0 in the positive control (Table 2). All data series were homogenous 
(cv<30%), and the arithmetic mean, which was used as a measure of central tendency, ranged from 
5.0 at 500 IU of catalase to 297 in the positive control. 
 
Table 2. Basic statistical parameters of TCSs in the experiment with co-treatment with 
tulathromycin and catalase (n=4) 
Treatment Mean Min. Max. 
Lower 
quartil 
Upper 
quartil 
Coef. of 
var. 
Negative control (K) 5.50 5.00 6.00 5.00 6.00 9.09 
T 17.00 16.00 18.00 16.00 18.00 5.88 
T+CAT 100IU 8.50 8.00 9.00 8.00 9.00 5.88 
T+CAT 500IU 7.50 7.00 8.00 7.00 8.00 6.67 
CAT 500IU 5.00 4.00 6.00 4.00 6.00 20.00 
CAT 500IU+K+ 58.00 49.00 67.00 49.00 67.00 15.52 
Positive control (K+) 297.00 287.00 307.00 287.00 307.00 3.37 
Negative control: 0 µM of tulathormycin (K-); positive control: 100 µM H2O2 (K+); 100 µM of tulathormycin (T); 100 and 
500 IU of catalase (CAT).  
 
 
Considering the values of the coefficients of variation parametric tests were used for      
further analysis. The results of ANOVA (F=1321.137, p<0.001) showed very significant 
difference in mean TCS values between the treatments. According to the result of Tukey test, this 
difference arose from two sources (Fig. 2). Firstly, a significant difference between the two 
positive controls, that is, the cultures treated with H2O2 alone and in addition of catalase, and 
secondly, the difference between each of these two controls incomparison to all other treatments 
(tulathromycin alone, tulathromycin in co-treatment with 100 IU and 500 IU of catalase, 500 IU of 
catalase and negative control). The insignificant difference between the effects of the treatment 
with tulathromycin only and in co-treatment with catalase proved that this enzyme did not reduce 
the damage of DNA caused by tulathromycin. The lack of difference between the effect of 500 IU 
of catalase and the negative control proved that this enzyme did not induce any DNA damage (Fig. 
2). 
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Figure 2. Effects of tulathromycin, catalase, negative and positive control on reduction of DNA damage 
inpurified rat lymphocytes as results of ANOVA and Tukey test 
Negative control: 0 µM of tulathormycin (K-); positive control: 100 µM H2O2 (K+); 100 µM of 
tulathormycin (T); 100 and 500 IU of catalase (CAT). The same letters indicate the lack of 
significant difference (p>0.05), while an absence of the same letters denotes the presence of 
statistical significance between experimental points -   based on the results of  Mann-Whitney U 
test.  
 
DISCUSSION 
Tulathromycin is the first member of triamilides, a relatively new subclass of macrolide 
antibiotics, specifically developed for the treatment of bacterial respiratory diseases in cattle and 
swine (BENCHAOUI et al., 2004; EMEA, 2004; EVANS, 2005). It accumulates in polymorphonuclear 
leukocytes and alveolar macrophages, it is also involved in the immune response to infection in the 
lung and is slowly released into the extracellular space where it acts directly on the pathogens of 
respiratory infections (ZHANEL et al., 2001; EVANS, 2005, KILGORE et al., 2005). 
           Although there are limited data about the cytotoxicity of macrolide antibiotics, the observed 
biological effects of tulathromycin and other macrolides point to some cytotoxic effects  
(FÜLÖPOVÁ et al., 2012). Interestingly, there are differences in the level of cytotoxicity depending 
on the type of the macrolides and/or the cell line used in the investigations.  On the other hand, 
there are no available data concerninig evaluation of genotoxic effect of tulathromyin using an in 
vitro comet assay.         
In the present research, only the highest concentrations (50 µM and 100 µM) of 
tulathromycin induced genotoxic effects significantly increasing the level of DNA damage in 
comparison to the negative control. However, the concentration of 50 µM was much higher than 
plasma peak concentration of tulathromycin in Holstein male calves (277 ng/g) (COX et al., 2010) 
treated with therapeutic dose of 2.5 mg/kg b.w. Anyway, the DNA damage caused by 
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tulathromycin at two highest concentrations is in agreement with the findings of WASHBURN et al. 
(2007), who showed that tulathromycin has a genotoxic potential. They used flow cytometry 
measured DNA content as a measure of chromosomal abnormalities associated with tulathromycin 
exposure and showed the increase in half-peak DNA coefficient of variation increased in the 
treatment group with each subsequent sampling, and that the mean was significantly higher in 
comparison to the control. They also suggested the need for additional genotoxicological studies of 
this product (WASHBURN et al., 2007). 
Some literature data suggested that tulathromycin causes oxidative stress (ER et al., 2011). 
Oxidative stress is a cell condition which occurs when the production of reactive oxygen species 
(ROS) exceeds cellular defence mechanisms (DJELIĆ and ANDERSON, 2003; RADAKOVIĆ et al., 
2011; RADAKOVIĆ et al., 2013). ROS can be detrimental to cells due to oxidative damage to DNA, 
essential enzymes and structural proteins and the induction of an uncontrolled chain reactions 
(such as lipid peroxidation or auto-oxidation) (COVARRUBIAS et al., 2008). Antioxidant enzymes 
play a role in the removal of various ROS (O’BRIEN, 2000; MAIER and CHAN, 2002; KIRKMAN and 
GAETANI, 2007). It has been reported that tulathromycin increased the levels of serum 
malondialdehyde, nitric oxide and superoxide dismutase and decreased the level of antithrombin 
III in rabbits (ER et al., 2011). 
 In the current research the co-treatment with catalase was performed in order to establish 
whether OH• induced the damages of DNA. It is known that catalases are enzymes that protect the 
cell from free radical-induced damage by degradation of hydrogen peroxide, thus preventing its 
accumulation and toxic action (EJCHART, 2001). We showed that catalase did not reduce the 
tulathromycin-mediated damage of DNA, which indicates that catalase did not exert significant 
protective effect. However, it is possible that hydrogen peroxide is not formed in reaction of 
tulathromycin and molecular oxygen and that some other reactive oxygen species (for example 
superoxide anion) is generated by tulathromycin.  
In conclusion, our data demonstrate that tulathromycin was capable to induce DNA damage 
only at very high concentrations that exceed therapeutic doses in veterinary medicine. Further 
analysis, especially under in vivo conditions, may provide a new insight in possible genotoxic 
effects of tulathromycin.  
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Izvod 
Tulatromicin je relativno nov polusintetički makrolidni antibiotik, član grupe triamilida, koji 
ima primenu u lečenju respiratornih bolesti kod goveda i svinja. Različite genotoksikološe 
studije pokazuju da tulatromicin nije genotoksičan, ali nema raspoloživih publikovanih 
podataka u kojima se primenjuje komet test (test elektroforeze pojedinačnih ćelija . Stoga, cilj 
ovog rada je bio da se ispita da li tulatromicin može izazvati oštećenje DNK primenom in 
vitro Komet testa u izolovanim limfocitima pacova. Limfociti su tretirani širokim spektrom 
koncentracija tulatromicina (od 1 do 100 uM) i obavljen je ko-tretman sa antioksidansom 
katalazom (100 IU/mL i 500 IU/mL). Najveća koncentracija tulatromicina (50 i 100 µM) 
indukovala je značajno povećanje oštećenja DNK u limfocitima pacova, dok katalaza nije 
značajno redukovala stepen oštećenja DNK pod dejstvom tulatromicina. Rezultati ove studije 
pokazuju da je tulatromicin indukovao genotoksične efekte pri visokim koncentracijama, a 
katalaza nije ispoljila protektivan efekat u ovoj studiji. 
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